Triheptanoin for the treatment of brain energy deficit: A 14-year experience

Journal of Neuroscience Research

Volumn 95, Issue 11, 2017, Pages 2236-2243

  Mochel, Fanny ^a,b  

^a SORBONNE UNIVERSITÉ   (France)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

astrocytes; GLUT1; Huntington disease; Krebs cycle; magnetic resonance spectroscopy

Indexed keywords

TRIHEPTANOIN; GLUCOSE; TRIACYLGLYCEROL;

BRAIN; BRAIN DISEASE; DISEASE MODEL; ENERGY; ENERGY METABOLISM; GLUCOSE TRANSPORTER 1 DEFICIENCY SYNDROME; HUMAN; HUNTINGTON CHOREA; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEFICIENCY; PYRUVATE CARBOXYLASE DEFICIENCY; REVIEW; SYNDROME; ANIMAL; DRUG EFFECT; METABOLISM; PHYSIOLOGY;

ANIMALS; BRAIN; ENERGY METABOLISM; GLUCOSE; HUMANS; TRIGLYCERIDES;

EID: 85022178731     PISSN: 03604012     EISSN: 10974547     Source Type: Journal    
DOI: 10.1002/jnr.24111     Document Type: Review

References (62)

1. Adanyeguh IM, Rinaldi D, Henry PG, Caillet S, Valabregue R, Durr A, Mochel F. 2015. Triheptanoin improves brain energy metabolism in patients with Huntington disease. Neurology 84:490–495.
2. Antonini A, Leenders KL, Spiegel R, Meier D, Vontobel P, Weigell-Weber M, Sanchez-Pernaute R, de Yébenez JG, Boesiger P, Weindl A, et al. 1996. Striatal glucose metabolism and dopamine D2 receptor binding in asymptomatic gene carriers and patients with Huntington's disease. Brain 119(Pt. 6):2085–2095.
3. Aziz NA, van der Burg JM, Landwehrmeyer GB, Brundin P, Stijnen T, EHDI Study Group, Roos RA. 2008. Weight loss in Huntington disease increases with higher CAG repeat number. Neurology 71:1506–1513.
4. Breen C, White FJ, Scott CA, Heptinstall L, Walter JH, Jones SA, Morris AA. 2014. Unsuccessful treatment of severe pyruvate carboxylase deficiency with triheptanoin. Eur J Pediatr 173:361–366.
5. Brouillet E, Guyot MC, Mittoux V, Altairac S, Condé F, Palfi S, Hantraye P. 1998. Partial inhibition of brain succinate deshydrogenase is sufficient to initiate striatal degeneration in rat. Journal of Neurochemistry 70:794–805.
6. Browne SE, Beal MF. 2004. The energetics of Huntington's disease. Neurochem Res 29:531–546.
7. Cui L, Jeong H, Borovecki F, Parkhurst CN, Tanese N, Krainc D. 2006. Transcriptional repression of PGC-1alpha by mutant huntingtin leads to mitochondrial dysfunction and neurodegeneration. Cell 127:59–69.
8. De Vivo DC, Trifiletti RR, Jacobson RI, Ronen GM, Behmand RA, Harik SI. 1991. Defective glucose transport across the blood-brain barrier as a cause of persistent hypoglycorrhachia, seizures, and developmental delay. N Engl J Med 325:703–709.
9. Deng S, Zhang GF, Kasumov T, Roe CR, Brunengraber H. 2009. Interrelations between C4 ketogenesis, C5 ketogenesis, and anaplerosis in the perfused rat liver. J Biol Chem 284:27799–27807.
10. Dienel GA. 2017. Lack of appropriate stoichiometry: strong evidence against an energetically important astrocyte-neuron lactate shuttle in brain. J Neurosci Res 95:2103–2125.
11. Ebert D, Haller RG, Walton ME. 2003. Energy contribution of octanoate to intact rat brain metabolism measured by 13C nuclear magnetic resonance spectroscopy. J Neurosci 23:5928.
12. Francis JS, Markov V, Leone P. 2014. Dietary triheptanoin rescues oligodendrocyte loss, dysmyelination and motor function in the nur7 mouse model of Canavan disease. J Inherit Metab Dis 37:369–381.
13. Funfschilling U, Supplie LM, Mahad D, Boretius S, Saab AS, Edgar J, Brinkmann BG, Kassmann CM, Tzvetanova ID, Möbius W, et al. 2012. Glycolytic oligodendrocytes maintain myelin and long-term axonal integrity. Nature 485:517–521.
14. Gines S, Seong IS, Fossale E, Ivanova E, Trettel F, Gusella JF, Wheeler VC, Persichetti F, MacDonald ME. 2003. Specific progressive cAMP reduction implicates energy deficit in presymptomatic Huntington's disease knock-in mice. Hum Mol Genet 12:497–508.
15. Goodman AO, Murgatroyd PR, Medina-Gomez G, Wood NI, Finer N, Vidal-Puig AJ, Morton AJ, Barker RA. 2008. The metabolic profile of early Huntington's disease—a combined human and transgenic mouse study. Exp Neurol 210:691–698.
16. Gras D, Cousin C, Kappeler C, Fung CW, Auvin S, Essid N, Hy Chung B, Da Costa L, Hainque E, Luton MP, et al. 2017. A simple blood test expedites the diagnosis of GLUT1 deficiency syndrome. Ann Neurol 82:133–138.
17. Gras D, Roze E, Caillet S, Meneret A, Doummar D, Billette de Villemeur T, Vidailhet M, Mochel F. 2014. GLUT1 deficiency syndrome: an update. Rev Neurol (Paris) 170:91–99.
18. Gu L, Zhang GF, Kombu RS, Allen F, Kutz G, Brewer WU, Roe CR, Brunengraber H. 2010. Parenteral and enteral metabolism of anaplerotic triheptanoin in normal rats. II. Effects on lipolysis, glucose production, and liver acyl-CoA profile. Am J Physiol Endocrinol Metab 298:E362–E371.
19. Hadera MG, Smeland OB, McDonald TS, Tan KN, Sonnewald U, Borges K. 2014. Triheptanoin partially restores levels of tricarboxylic acid cycle intermediates in the mouse pilocarpine model of epilepsy. J Neurochem 129:107–119.
20. Hertz L. 2004. The astrocyte-neuron lactate shuttle: a challenge of a challenge. J Cereb Blood Flow Metab 24:1241–1248.
21. Huntington's Disease Collaborative Research Group. 1993. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 72:971–983.
22. Kinman RP, Kasumov T, Jobbins KA, Thomas KR, Adams JE, Brunengraber LN, Kutz G, Brewer WU, Roe CR, Brunengraber H. 2006. Parenteral and enteral metabolism of anaplerotic triheptanoin in normal rats. Am J Physiol Endocrinol Metab 291:E860–E866.
23. Klepper J. 2012. GLUT1 deficiency syndrome in clinical practice. Epilepsy Res 100:272–277.
24. Klepper J, Leiendecker B. 2013. Glut1 deficiency syndrome and novel ketogenic diets. J Child Neurol 28:1045–1048.
25. Klepper J, Leiendecker B, Bredahl R, Athanassopoulos S, Heinen F, Gertsen E, Flörcken A, Metz A, Voit T. 2002. Introduction of a ketogenic diet in young infants. J Inherit Metab Dis 25:449–460.
26. Klepper J, Scheffer H, Leiendecker B, Gertsen E, Binder S, Leferink M, Hertzberg C, Näke A, Voit T, Willemsen MA. 2005. Seizure control and acceptance of the ketogenic diet in GLUT1 deficiency syndrome: a 2- to 5-year follow-up of 15 children enrolled prospectively. Neuropediatrics 36:302–308.
27. Leen WG, Klepper J, Verbeek MM, Leferink M, Hofste T, van Engelen BG, Wevers RA, Arthur T, Bahi-Buisson N, Ballhausen D, et al. 2010. Glucose transporter-1 deficiency syndrome: the expanding clinical and genetic spectrum of a treatable disorder. Brain 133(Pt. 3):655–670.
28. Leen WG, Wevers RA, Kamsteeg EJ, Scheffer H, Verbeek MM, Willemsen MA. 2013. Cerebrospinal fluid analysis in the workup of GLUT1 deficiency syndrome: a systematic review. JAMA Neurol 70:14440–11444.
29. Lin J, Handschin C, Spiegelman BM. 2005. Metabolic control through the PGC-1 family of transcription coactivators. Cell Metab 1:361–370.
30. Lin J, Wu PH, Tarr PT, Lindenberg KS, St-Pierre J, Zhang CY, Mootha VK, Jäger S, Vianna CR, Reznick RM, et al. 2004. Defects in adaptive energy metabolism with CNS-linked hyperactivity in PGC-1alpha null mice. Cell 119:121–135.
31. Marin-Valencia I, Good LB, Ma Q, Duarte J, Bottiglieri T, Sinton CM, Heilig CW, Pascual JM. 2012. Glut1 deficiency (G1D): epilepsy and metabolic dysfunction in a mouse model of the most common human phenotype. Neurobiol Dis 48:92–101.
32. Marin-Valencia I, Good LB, Ma Q, Malloy CR, Pascual JM. 2013. Heptanoate as a neural fuel: energetic and neurotransmitter precursors in normal and glucose transporter I-deficient (G1D) brain. J Cereb Blood Flow Metab 33:175–182.
33. Milakovic T, Johnson GV. 2005. Mitochondrial respiration and ATP production are significantly impaired in striatal cells expressing mutant huntingtin. J Biol Chem 280:30773–30782.
34. Mochel F, Charles P, Seguin F, Barritault J, Coussieu C, Perin L, Le Bouc Y, Gervais C, Carcelain G, Vassault A, et al. 2007. Early energy deficit in Huntington disease: identification of a plasma biomarker traceable during disease progression. PLoS One 2:e647.
35. Mochel F, DeLonlay P, Touati G, Brunengraber H, Kinman RP, Rabier D, Roe CR, Saudubray JM. 2005. Pyruvate carboxylase deficiency: clinical and biochemical response to anaplerotic diet therapy. Mol Genet Metab 84:305–312.
36. Mochel F, Durant B, Meng X, O'Callaghan J, Yu H, Brouillet E, Wheeler VC, Humbert S, Schiffmann R, Durr A. 2012. Early alterations of brain cellular energy homeostasis in Huntington disease models. J Biol Chem 287:1361–1370.
37. Mochel F, Duteil S, Marelli C, Jauffret C, Barles A, Holm J, Sweetman L, Benoist JF, Rabier D, Carlier PG, et al. 2010. Dietary anaplerotic therapy improves peripheral tissue energy metabolism in patients with Huntington's disease. Eur J Hum Genet 18:1057–1060.
38. Mochel F, Hainque E, Gras D, Adanyeguh IM, Caillet S, Heron B, Roubertie A, Kaphan E, Valabregue R, Rinaldi D, et al. 2016. Triheptanoin dramatically reduces paroxysmal motor disorder in patients with GLUT1 deficiency. J Neurol Neurosurg Psychiatry 87:550–553.
39. Mochel F, N'Guyen TM, Deelchand D, Rinaldi D, Valabregue R, Wary C, Carlier PG, Durr A, Henry PG. 2012. Abnormal response to cortical activation in early stages of Huntington disease. Mov Disord 27:907–910.
40. Palfi S, Ferrante RJ, Brouillet E, Beal MF, Dolan R, Guyot MC, Peschanski M, Hantraye P. 1996. Chronic 3-nitropropionic acid treatment in baboons replicates the cognitive and motor deficits of Huntington's disease. J Neurosci 16:3019–3025.
41. Park MJ, Aja S, Li Q, Degano AL, Penati J, Zhuo J, Roe CR, Ronnett GV. 2014. Anaplerotic triheptanoin diet enhances mitochondrial substrate use to remodel the metabolome and improve lifespan, motor function, and sociability in MeCP2-null mice. PLoS One 9:e109527.
42. Pascual JM, Liu P, Mao D, Kelly DI, Hernandez A, Sheng M, Good LB, Ma Q, Marin-Valencia I, Zhang X, et al. 2014. Triheptanoin for glucose transporter type I deficiency (G1D): modulation of human ictogenesis, cerebral metabolic rate, and cognitive indices by a food supplement. JAMA Neurol 71:1255–1265.
43. Paulsen JS, Langbehn DR, Stout JC, Aylward E, Ross CA, Nance M, Guttman M, Johnson S, MacDonald M, Beglinger LJ, et al.; Predict-HD Investigators and Coordinators of the Huntington Study Group. 2008. Detection of Huntington's disease decades before diagnosis: the Predict-HD study. J Neurol Neurosurg Psychiatry, 79:874–880.
44. Perry TL, Diamond S, Hansen S, Stedman D. 1969. Plasma-aminoacid levels in Huntington's chorea. Lancet 1:806–808.
45. Pons R, Collins A, Rotstein M, Engelstad K, De Vivo DC. 2010. The spectrum of movement disorders in Glut-1 deficiency. Mov Disord 25:275–281.
46. Roe CR, Bottiglieri T, Wallace M, Arning E, Martin A. 2010. Adult polyglucosan body disease (APBD): anaplerotic diet therapy (triheptanoin) and demonstration of defective methylation pathways. Mol Genet Metab 101:246–252.
47. Roe CR, Mochel F. 2006. Anaplerotic diet therapy in inherited metabolic disease: therapeutic potential. J Inherit Metab Dis 29:332–340.
48. Roe CR, Sweetman L, Roe DS, David F, Brunengraber H. 2002. Treatment of cardiomyopathy and rhabdomyolysis in long-chain fat oxidation disorders using an anaplerotic odd-chain triglyceride. J Clin Invest 110:259–269.
49. Roe CR, Yang BZ, Brunengraber H, Roe DS, Wallace M, Garritson BK. 2008. Carnitine palmitoyltransferase II deficiency: successful anaplerotic diet therapy. Neurology 71:260–264.
50. Sappey-Marinier D, Calabrese G, Fein G, Hugg JW, Biggins C, Weiner MW. 1992. Effect of photic stimulation on human visual cortex lactate and phosphates using 1H and 31P magnetic resonance spectroscopy. J Cereb Blood Flow Metab 12:584–592.
51. Shank RP, Bennett GS, Freytag SO, Campbell GL. 1985. Pyruvate carboxylase: an astrocyte-specific enzyme implicated in the replenishment of amino acid neurotransmitter pools. Brain Res 329:364–367.
52. Supplie LM, Düking T, Campbell G, Diaz F, Moraes CT, Götz M, Hamprecht B, Boretius S, Mahad D, Nave KA. 2017. Respiration-deficient astrocytes survive as glycolytic cells in vivo. J Neurosci 37:4231–4242.
53. Tabrizi SJ, Cleeter MW, Xuereb J, Taanman JW, Cooper JM, Schapira AH. 1999. Biochemical abnormalities and excitotoxicity in Huntington's disease brain. Ann Neurol 45:25–32.
54. Tabrizi SJ, Scahill RI, Owen G, Durr A, Leavitt BR, Roos RA, Borowsky B, Landwehrmeyer B, Frost C, Johnson H, et al.; TRACK-HD Investigators. 2013. Predictors of phenotypic progression and disease onset in premanifest and early-stage Huntington's disease in the TRACK-HD study: analysis of 36-month observational data. Lancet Neurol 12:637–649.
55. Verrotti A, D'Egidio C, Agostinelli S, Gobbi G. 2012. Glut1 deficiency: when to suspect and how to diagnose? Eur J Paediatr Neurol 16:3–9.
56. Vockley J, Charrow J, Ganesh J, Eswara M, Diaz GA, McCracken E, Conway R, Enns GM, Starr J, Wang R, et al. 2016. Triheptanoin treatment in patients with pediatric cardiomyopathy associated with long chain-fatty acid oxidation disorders. Mol Genet Metab 119:223–231.
57. Vockley J, Marsden D, McCracken E, DeWard S, Barone A, Hsu K, Kakkis E. 2015. Long-term major clinical outcomes in patients with long chain fatty acid oxidation disorders before and after transition to triheptanoin treatment—a retrospective chart review. Mol Genet Metab 116:53–60.
58. Volkenhoff A, Weiler A, Letzel M, Stehling M, Klambt C, Schirmeier S. 2015. Glial glycolysis is essential for neuronal survival in drosophila. Cell Metab 22:437.
59. Wiener DH, Fink LI, Maris J, Jones RA, Chance B, Wilson JR. 1986. Abnormal skeletal muscle bioenergetics during exercise in patients with heart failure: role of reduced muscle blood flow. Circulation 73:1127–1136.
60. Willis S, Stoll J, Sweetman L, Borges K. 2010. Anticonvulsant effects of a triheptanoin diet in two mouse chronic seizure models. Neurobiol Dis 40:565–572.
61. Yang H, Wang D, Engelstad K, Bagay L, Wei Y, Rotstein M, Aggarwal V, Levy B, Ma L, Chung WK, et al. 2011. Glut1 deficiency syndrome and erythrocyte glucose uptake assay. Ann Neurol 70:996–1005.
62. Zhang Y, Chen K, Sloan SA, Bennett ML, Scholze AR, O'Keeffe S, Phatnani HP, Guarnieri P, Caneda C, Ruderisch N, et al. 2014. An RNA-sequencing transcriptome and splicing database of glia, neurons, and vascular cells of the cerebral cortex. J Neurosci 34:11929.